Phosphoethanolamine and omega-3 in patients with asthma

The effect of omega-3 (n-3) in asthma has been inconclusive. One explanation for it may be the low incorporation of these fatty acids in clinical studies. Phosphoethanolamine (PEtn) can increase the synthesis of phosphatidylethanolamine, which can, in turn, increase the incorporation of n-3 in cell membranes. The aim of this study is to evaluate the effect of synthetic PEtn in patients with asthma who are receiving n-3. This randomized, double-blind, placebo-controlled study was carried out over a two month period by using spirometry, the Asthma Control Test questionnaire (ACT) and medicine intake. Forty-one patients with asthma were studied. Twenty-one patients received n-3 daily (1.080 mg of EPA, 720 mg of DHA) and 800 mg of PEtn (PEtn group), and twenty patients received the same doses of n-3 and placebo (control group). All patients continued receiving their conventional treatment for asthma. The hospital ethics committee approved the study. Five patients of each group required systemic corticosteroids, being the total consumption, smaller in the PEtn group (127.4 mg of prednisone/patient versus 416.0 mg of prednisone/patient in the control group, p-value = 0.0269). There were no significant differences in the changing of ATC and FEV1, as well as in the intake of formoterol or budesonide between the groups. In this study, patients who received phosphoethanolamine and omega-3 needed a smaller dose of systemic corticosteroid for asthma control than patients who only received omega-3. However, as the trial was conducted on a small scale, more studies are necessary

Polarographic and Spectrophotometric Study of Lead Complexes with Diethanoldithiocarbamate

Experimental and theoretical aspects concerning the behaviour of lead-dietanoldithiocarbamate complexes in aqueous solutions were studied. The reaction occurs through complexation and formation of a yellow precipitate, which is soluble in ligand excess and in some polar solvents. The results from elementary and gravimetric analyses show a stoichiometric relationship of 1:2 (Pb(II): DEDC). Some ambiguous interpretations have been clarified on the application in this system of Lingane?s equation. Polarographic measurements were used to determine the coordination number (<FONT FACE=Symbol>@</FONT> 3.0) and overall formation constant betaMLn (<FONT FACE=Symbol>@</FONT> 4 x 10(16)), of the lead complexes with ammonium diethanoldithiocarbamate, which show a good agreement with previous potentiometric results for the same system. A kinetic-spectrophotometric study was carried out in order to establish the decomposition of these complexes in acid medium

Polarographic and Spectrophotometric Study of Lead Complexes with Diethanoldithiocarbamate

Experimental and theoretical aspects concerning the behaviour of lead-dietanoldithiocarbamate complexes in aqueous solutions were studied. The reaction occurs through complexation and formation of a yellow precipitate, which is soluble in ligand excess and in some polar solvents. The results from elementary and gravimetric analyses show a stoichiometric relationship of 1:2 (Pb(II): DEDC). Some ambiguous interpretations have been clarified on the application in this system of Lingane’s equation. Polarographic measurements were used to determine the coordination number (<FONT FACE=Symbol>@</FONT> 3.0) and overall formation constant betaMLn (<FONT FACE=Symbol>@</FONT> 4 x 10(16)), of the lead complexes with ammonium diethanoldithiocarbamate, which show a good agreement with previous potentiometric results for the same system. A kinetic-spectrophotometric study was carried out in order to establish the decomposition of these complexes in acid medium

Determinacao de Aluminio Toxico as Raizes do Trigo por Potenciometria com Eletrodo Seletivo de Fluoreto.

Avaliou-se o metodo potenciometrico com o eletrodo seletivo de fluoreto (ESIF) para estimar as especies toxicas de Al as raizes do trigo em solucoes pura e de solo e em solos acidos tratados com doses de calcario. Comparou-se Al-ESIF com o método espectrofotométrico com a solucao de ferron. O crescimento das raizes diminuiu exponencialmente com o aumento de Al--ESIF, cuja tecnica detectou principalmente as especies A13+, Al(OH)2+ e Al(OH)2+. A concentracao de Al-ESIF nos solos sem calcario (pH 4,0) variou de 30 a 2100 x 10-6M e diminuiu com o aumento do pH ate valores nao detectaveis em pH > 5,6. Al-ferron foi superior ao Al-ESIF em todos os pH estudados. Os complexos de A1 em pH > 5,6 foram reativos com ferron, mas nao com F-. -Al-ESIF apresentou a melhor estimativa das especies toxicas de Al as raizes do trigo.Made available in DSpace on 2011-04-09T12:13:02Z (GMT). No. of bitstreams: 1 pab10ago93.pdf: 280082 bytes, checksum: 0eeac35a25a7fcc343c6e7daff20ec28 (MD5) Previous issue date: 2001-08-16199

Long-term assessment of a modified tibial tuberosity advancement technique in dogs

ABSTRACT The purpose of study was to assess long-term clinical and radiographic aspects of dogs’ stifle joints which had undergone a modified tibial tuberosity advancement technique (mTTA). A total of 15 stifles that had undergone mTTA for CCL disease of 11 patients were included in this study. Assessments involved patient’s gait analysis, cranial drawer and tibial compression tests, stifle goniometry range of articular motion, thigh and leg girth and radiographic evidence of progression of osteoarthrosis. Variables were compared between operated and healthy limbs and among moments (M0) on the early postop; (M1) 120 days postop; and (M2) approximately 5 years following surgery. A questionnaire regarding owner’s perceptions after approximately 5 years of surgery was assessed. Most dogs presented positive response to cranial drawer and tibial compression tests on operated knees. There was also decrease on goniometry and thigh girth and increase in leg girth. Radiographic evidence of progression of osteoarthritis was seen especially on the long-term follow-up (M2). On gait analysis, most animals presented some degree of lameness in different conditions, in contrast to owners’ perceptions. Osteoarthritis still develops in dogs following mTTA surgery for CCL disease. However, owners were overall satisfied with their recovery and would be willing to accept indication of mTTA for dogs with ruptured CCL

Phosphoethanolamine and omega-3 in patients with asthma

The effect of omega-3 (n-3) in asthma has been inconclusive. One explanation for it may be the low incorporation of these fatty acids in clinical studies. Phosphoethanolamine (PEtn) can increase the synthesis of phosphatidylethanolamine, which can, in turn, increase the incorporation of n-3 in cell membranes. The aim of this study is to evaluate the effect of synthetic PEtn in patients with asthma who are receiving n-3. This randomized, double-blind, placebo-controlled study was carried out over a two month period by using spirometry, the Asthma Control Test questionnaire (ACT) and medicine intake. Forty-one patients with asthma were studied. Twenty-one patients received n-3 daily (1.080 mg of EPA, 720 mg of DHA) and 800 mg of PEtn (PEtn group), and twenty patients received the same doses of n-3 and placebo (control group). All patients continued receiving their conventional treatment for asthma. The hospital ethics committee approved the study. Five patients of each group required systemic corticosteroids, being the total consumption, smaller in the PEtn group (127.4 mg of prednisone/patient versus 416.0 mg of prednisone/patient in the control group, p-value = 0.0269). There were no significant differences in the changing of ATC and FEV1, as well as in the intake of formoterol or budesonide between the groups. In this study, patients who received phosphoethanolamine and omega-3 needed a smaller dose of systemic corticosteroid for asthma control than patients who only received omega-3. However, as the trial was conducted on a small scale, more studies are necessary

Phosphoethanolamine and omega-3 in patients with asthma

The effect of omega-3 (n-3) in asthma has been inconclusive. One explanation for it may be the low incorporation of these fatty acids in clinical studies. Phosphoethanolamine (PEtn) can increase the synthesis of phosphatidylethanolamine, which can, in turn, increase the incorporation of n-3 in cell membranes. The aim of this study is to evaluate the effect of synthetic PEtn in patients with asthma who are receiving n-3. This randomized, double-blind, placebo-controlled study was carried out over a two month period by using spirometry, the Asthma Control Test questionnaire (ACT) and medicine intake. Forty-one patients with asthma were studied. Twenty-one patients received n-3 daily (1.080 mg of EPA, 720 mg of DHA) and 800 mg of PEtn (PEtn group), and twenty patients received the same doses of n-3 and placebo (control group). All patients continued receiving their conventional treatment for asthma. The hospital ethics committee approved the study. Five patients of each group required systemic corticosteroids, being the total consumption, smaller in the PEtn group (127.4 mg of prednisone/patient versus 416.0 mg of prednisone/patient in the control group, p-value = 0.0269). There were no significant differences in the changing of ATC and FEV1, as well as in the intake of formoterol or budesonide between the groups. In this study, patients who received phosphoethanolamine and omega-3 needed a smaller dose of systemic corticosteroid for asthma control than patients who only received omega-3. However, as the trial was conducted on a small scale, more studies are necessary

Phosphoethanolamine and omega-3 in patients with asthma

The effect of omega-3 (n-3) in asthma has been inconclusive. One explanation for it may be the low incorporation of these fatty acids in clinical studies. Phosphoethanolamine (PEtn) can increase the synthesis of phosphatidylethanolamine, which can, in turn, increase the incorporation of n-3 in cell membranes. The aim of this study is to evaluate the effect of synthetic PEtn in patients with asthma who are receiving n-3. This randomized, double-blind, placebo-controlled study was carried out over a two month period by using spirometry, the Asthma Control Test questionnaire (ACT) and medicine intake. Forty-one patients with asthma were studied. Twenty-one patients received n-3 daily (1.080 mg of EPA, 720 mg of DHA) and 800 mg of PEtn (PEtn group), and twenty patients received the same doses of n-3 and placebo (control group). All patients continued receiving their conventional treatment for asthma. The hospital ethics committee approved the study. Five patients of each group required systemic corticosteroids, being the total consumption, smaller in the PEtn group (127.4 mg of prednisone/patient versus 416.0 mg of prednisone/patient in the control group, p-value = 0.0269). There were no significant differences in the changing of ATC and FEV1, as well as in the intake of formoterol or budesonide between the groups. In this study, patients who received phosphoethanolamine and omega-3 needed a smaller dose of systemic corticosteroid for asthma control than patients who only received omega-3. However, as the trial was conducted on a small scale, more studies are necessary

Long-term assessment of a modified tibial tuberosity advancement technique in dogs

<div><p>ABSTRACT The purpose of study was to assess long-term clinical and radiographic aspects of dogs’ stifle joints which had undergone a modified tibial tuberosity advancement technique (mTTA). A total of 15 stifles that had undergone mTTA for CCL disease of 11 patients were included in this study. Assessments involved patient’s gait analysis, cranial drawer and tibial compression tests, stifle goniometry range of articular motion, thigh and leg girth and radiographic evidence of progression of osteoarthrosis. Variables were compared between operated and healthy limbs and among moments (M0) on the early postop; (M1) 120 days postop; and (M2) approximately 5 years following surgery. A questionnaire regarding owner’s perceptions after approximately 5 years of surgery was assessed. Most dogs presented positive response to cranial drawer and tibial compression tests on operated knees. There was also decrease on goniometry and thigh girth and increase in leg girth. Radiographic evidence of progression of osteoarthritis was seen especially on the long-term follow-up (M2). On gait analysis, most animals presented some degree of lameness in different conditions, in contrast to owners’ perceptions. Osteoarthritis still develops in dogs following mTTA surgery for CCL disease. However, owners were overall satisfied with their recovery and would be willing to accept indication of mTTA for dogs with ruptured CCL.</p></div